Abzena Secures ADC Manufacturing Contract with US Biotech Firm

Dec 14, 2017
By Pharmaceutical Technology Editors

Abzena, a biopharmaceutical service provider, announced on Dec. 11, 2017 that it has entered into a Master Services Agreement with a US biotech company to provide process development and manufacturing services to progress a novel antibody-drug conjugate (ADC) to clinical trials.

The value of the entire process development and GMP manufacturing services is more than $5 million, with the majority of the services to be provided within the next 12 months. The services will be carried out principally by Abzena’s chemistry and biomanufacturing groups in Bristol, PA and San Diego, CA.

Abzena has worked with the US-based company for a number of years offering its chemistry services. Following the initial chemistry development, Abzena subsequently developed a cell line that will now be used to produce the antibody at its GMP manufacturing facility. Abzena will also conduct GMP production of the ADC payload reagent and the conjugation process to create the ADC for initial clinical study.

In entering into the Master Services Agreement with Abzena, the US biotech company has selected Abzena as its preferred chemistry services and manufacturing provider for its ADC program.

Source: Abzena

lorem ipsum